DNMT3A and acute myeloid leukemia: In the meantime, we found that high BRAF expression and TET2 and DNMT3A mutations were more commonly found in elderly AML patients, and that the survival time of these AML patients carrying TET2 and DNMT3A was shortened by high BRAF expression.